Dimethylsulfoxide-treated, cryopreserved venous allografts in the arterial and venous systems.
Autologous saphenous vein is the preferred conduit for most vascular reconstructive procedures; however, many authorities have emphasized the need for a reliable alternate. This study was designed to assess the short-term patency of dimethylsulfoxide-treated, cryopreserved saphenous vein allografts in both high- and low-flow states. An early patency rate of 58.3% was found for such allografts interposed in the arterial system. No instance of aneurysm formation was noted. Allografts interposed in the venous system uniformly occluded within 5 weeks. However, in animals treated with aspirin and dipyridamole there was an 83% early patency rate for cryopreserved allografts in the venous system. These studies suggest that dimethylsulfoxide cryopreservation is a viable technique for venous allograft preservation as demonstrated by satisfactory short-term patency of grafts implanted in the arterial system. The results also suggest that treatment with aspirin and dipyridamole has a beneficial effect on the early patency of such grafts placed in the venous system.
D000818:Animals; D001158:Arteries / Q000601:surgery; D001241:Aspirin / Q000494:pharmacology; D004121:Dimethyl Sulfoxide / Q000494:pharmacology*; D004176:Dipyridamole / Q000494:pharmacology; D004285:Dogs; D005615:Freezing; D006085:Graft Survival; D007601:Jugular Veins / Q000637:transplantation; D008297:Male; D012501:Saphenous Vein / Q000601:surgery; D014021:Tissue Preservation / Q000379:methods*; D014184:Transplantation, Homologous; D014680:Veins / Q000601:surgery / Q000637:transplantation*
D004176:Dipyridamole; D001241:Aspirin; D004121:Dimethyl Sulfoxide